Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseases | Patent Number 11787862

US 11787862 B2
Application Number16335373
Publication NumberUS 20190309067 A1
Pendency6 years, 28 days
Filled DateSep 20, 2017
Priority DateSep 20, 2017
Publication DateOct 10, 2019
Expiration DateSep 19, 2037
Inventor/ApplicantsLeyla Fischer
Christiane Stadler
Ozlem Tureci
Arne Jendretzki
Maria Kreuzberg
Ugur Sahin
Fabrice Le Gall
ExaminesCHEONG, CHEOM-GIL
Art Unit1645
Technology Center1600
Assignments
Biontech Ag
Current
Biontech Ag
Original
Astellas Pharma Inc.
Original
Law Firm
You must be logged in to view
Login
Attorneys
Subscription-Only
View Concierge Program
Patent Prosecution report image

Empower your practice with Patexia Publication Prosecution IP Module.

Get access to our exclusive rankings and unlock powerful data.
Check our Latest ReportPurchase IP Module

Looking for a Publication Attorney?

Get in touch with our team or create your account to start exploring a network of over 120K attorneys.